Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™
Lobe Sciences and Alera Pharma announce the issuance of U.S. Patent number 12,102,616 for Conjugated Psilocin™. The patent, titled 'Psilocin Mucate', covers compositions of matter, methods of use, and production for psilocin mucate. It will be valid until July 2043, subject to maintenance fees. Lobe Sciences will assign the intellectual property rights to Alera Pharma, its newly established wholly-owned subsidiary.
Conjugated Psilocin™ is a novel, oral, stable analogue of psilocin, addressing the instability issues of psilocin and poor bioavailability of psilocybin. The companies aim to develop it as a prescription medication for various neurological disorders, with a primary focus on Chronic Cluster Headache.
Lobe Sciences e Alera Pharma annunciano l'emissione del Brevetto Statunitense numero 12,102,616 per Conjugated Psilocin™. Il brevetto, intitolato 'Psilocin Mucate', copre composizioni di materia, metodi d'uso e produzione per il psilocina mucato. Sarà valido fino a luglio 2043, soggetto a commissioni di mantenimento. Lobe Sciences cederà i diritti di proprietà intellettuale ad Alera Pharma, la sua nuova consociata interamente controllata.
Conjugated Psilocin™ è un nuovo, stabile analogo orale della psilocina, che affronta i problemi di instabilità della psilocina e la bassa biodisponibilità della psilocibina. Le aziende intendono svilupparlo come medicinale da prescrizione per vari disturbi neurologici, con un focus principale sullEmicrania Cluster Cronica.
Lobe Sciences y Alera Pharma anuncian la emisión de Patente de EE. UU. número 12,102,616 para Conjugated Psilocin™. La patente, titulada 'Psilocin Mucate', cubre composiciones de materia, métodos de uso y producción para el mucato de psilocina. Será válida hasta julio de 2043, sujeta a tarifas de mantenimiento. Lobe Sciences asignará los derechos de propiedad intelectual a Alera Pharma, su nueva filial de propiedad absoluta.
Conjugated Psilocin™ es un nuevo análogo oral y estable de la psilocina, que aborda los problemas de inestabilidad de la psilocina y la baja biodisponibilidad de la psilocibina. Las empresas tienen como objetivo desarrollarlo como un medicamento recetado para varios trastornos neurológicos, con un enfoque principal en Cefalea en Racimos Crónica.
로브 사이언스와 알레라 제약은 미국 특허 번호 12,102,616을 결합된 실로시빈™에 대해 발표합니다. '실로시빈 무카테'라는 제목의 이 특허는 실로시빈 무카테의 물질 조성, 사용 방법 및 생산에 대해 다룹니다. 이 특허는 2043년 7월까지 유효하며, 유지 관리 수수료가 적용됩니다. 로브 사이언스는 지적 재산권을 전적으로 소유하는 자회사인 알레라 제약에 양도할 것입니다.
결합된 실로시빈™은 실로시빈의 불안정성 문제와 실로시빈의 낮은 생체 이용률을 해결하는 새로운 경구용 안정형 유사체입니다. 이 회사들은 이를 다양한 신경 질환에 대한 처방 약물로 개발할 목표를 가지고 있으며, 주요 초점은 만성 클러스터 두통입니다.
Lobe Sciences et Alera Pharma annoncent l'émission du Brevet américain numéro 12,102,616 pour Conjugated Psilocin™. Le brevet, intitulé 'Psilocin Mucate', couvre des compositions de matière, des méthodes d'utilisation et de production pour le mucate de psilocine. Il sera valide jusqu'en juillet 2043, sous réserve de frais de maintenance. Lobe Sciences cédera les droits de propriété intellectuelle à Alera Pharma, sa nouvelle filiale entièrement détenue.
Conjugated Psilocin™ est un analogue oral stable et novateur de la psilocine, qui répond aux problèmes d'instabilité de la psilocine et à la faible biodisponibilité de la psilocybine. Les entreprises visent à le développer comme médicament sur ordonnance pour divers troubles neurologiques, avec un accent particulier sur la Céphalée en Grappes Chronique.
Lobe Sciences und Alera Pharma geben die Ausstellung des US-Patents mit der Nummer 12,102,616 für Conjugated Psilocin™ bekannt. Das Patent mit dem Titel 'Psilocin Mucate' umfasst Stoffzusammensetzungen, Verwendungsmethoden und die Herstellung von Psilocin-Mucat. Es ist bis Juli 2043 gültig, vorbehaltlich von Wartungsgebühren. Lobe Sciences wird die geistigen Eigentumsrechte an Alera Pharma, ihrer neu gegründeten hundertprozentigen Tochtergesellschaft, übertragen.
Conjugated Psilocin™ ist ein neuartiger, stabiler oraler Analogen von Psilocin, der die Stabilitätsprobleme von Psilocin und die geringe Bioverfügbarkeit von Psilocybin anspricht. Die Unternehmen planen, es als verschreibungspflichtiges Medikament für verschiedene neurologische Störungen zu entwickeln, wobei der Schwerpunkt auf Chronischer Clusterkopfschmerz liegt.
- Issuance of U.S. Patent 12,102,616 for Conjugated Psilocin™, valid until July 2043
- Conjugated Psilocin™ offers improved stability and bioavailability compared to psilocin and psilocybin
- Potential for development as a prescription medication for various neurological disorders
- None.
-
U.S. Patent Office issues patent number 12,102,616 - Patent covers the compositions of matter, methods of use and methods of production for Conjugated Psilocin™
- Alera Pharma, Inc., (a newly established wholly owned subsidiary of Lobe Sciences), to proceed with fund-raising and clinical development of Conjugated Psilocin™ in neurological disorders
This newly issued patent contains claims covering compositions of matter, methods of use and methods of production for psilocin mucate. Subject to payment of patent maintenance fees in the third, seventh and eleventh years following the grant, the patent will be valid until expiration in July, 2043. The Company has also filed several additional patent applications with the intention of broadening the base of claims. In addition to filings with the USPTO, the Company has filed for international coverage of its intellectual property.
Mr. Rick Goulburn, CEO of Alera Pharma, Inc. stated, “We are excited to receive this foundational and broad patent on Conjugated Psilocin™ which recognizes the unique properties of this psilocin analogue invention. Psilocin alone is a very unstable molecule that to date, has not successfully been developed as an oral stable prescription medicine. Companies trying to develop treatments have had to rely on using the prodrug psilocybin which relies on conversion in the gut resulting in poor bioavailability, uptake, and related adverse effects. With Conjugated Psilocin™, we now have a stable, orally available psilocin that is rapidly and fully bioavailable. As a result, we believe that we can create an oral prescription medication that can be precisely dosed and developed for a variety of neurological disorders.”
Dr. Fred Sancilio, Chairman and CEO of Lobe Sciences also commented, “We are excited that this patent has issued and validated the unique opportunity to develop an oral and stable psilocin product. We are highly aware of the desperate need patients with Chronic Cluster Headache have for this medication and we are anxious to move this product through the FDA approval process as quickly and efficiently as possible. However, treating Chronic Cluster Headaches is not our final application of this new and exciting drug candidate, and its potential use to treat several other disorders that are currently being studied in clinical trials utilizing psilocybin are clearly on our radar.”
About Conjugated Psilocin™
Conjugated Psilocin™ is a novel, oral, stable analogue of psilocin, the active metabolite of the prodrug psilocybin. Psilocybin is a psychedelic compound that has been identified as having therapeutic potential in a variety of neurological conditions. Psilocybin is dephosphorylated to the active moiety psilocin with poor bioavailability and pharmacokinetics. Psilocin itself is a very unstable compound that has been difficult to develop as a pharmaceutical medicine. Conjugated Psilocin™ is a stable, highly bioavailable pharmaceutical ingredient with the potential to be developed as a prescription medicine in a variety of neurological disorders.
About Lobe Sciences Ltd.
Lobe Sciences, Ltd. is a commercial stage biotechnology company focused on developing transformative therapies for unmet medical needs. Through its subsidiaries, Alera Pharma, Inc. and Altemia, Inc., Lobe Sciences is developing patented drug candidates to treat chronic cluster headache (Alera) and innovative medical foods to address deficiencies commonly seen in sickle cell disease (Altemia). Lobe Sciences provides common services to its subsidiaries including accounting, finance, and general administrative services.
About Alera Pharma, Inc.
Alera Pharma, Inc. is a private subsidiary of Lobe Sciences, Ltd., dedicated to the development and commercialization of innovative pharmaceutical products. With a focus on addressing unmet medical needs, Alera Pharma is committed to improving patient outcomes in a variety of neurological disorders through cutting-edge research and development.
Cautionary Statement Regarding "Forward-Looking" Information
This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: the belief that the Company and Alera will be able to create an oral prescription medication that can be precisely dosed and developed for a variety of neurological disorders; the belief that patients with Chronic Cluster Headache have a need for Conjugated Psilocin™; the anticipated approval by the FDA, and the timing thereof; and the Company’s belief that psilocybin may be able to treat several other disorders, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” or occur.
Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: any prescription medication that is developed from Conjugated Psilocin™ can be precisely dosed and developed for a variety of neurological disorders; that there is a need for need for Conjugated Psilocin™; the Company will obtain FDA approval for Conjugated Psilocin™ and will be able to do so on an expedited timeline; and Conjugated Psilocin™ may have use in treatment of other disorders. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that: Conjugated Psilocin™ cannot be developed into a precisely dosed prescription medication; the need for Conjugated Psilocin™ is less significant than the Company and Alera anticipate; the Company will not obtain FDA approval for Conjugated Psilocin™ or will not be able to do so on the timeline anticipated; and Conjugated Psilocin™ will not have application in treatment of other disorders.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241001025532/en/
For further information:
Dr. Fred D. Sancilio, CEO
Lobe Sciences Ltd.
Investor and Media
Info@Lobesciences.com
www.lobesciences.com
Mr. Rick Goulburn, CEO
Alera Pharma, Inc.
Investor and Media
Info@Alerapharma.com
Source: Lobe Sciences, Ltd.
FAQ
What is the new patent issued to Lobe Sciences and Alera Pharma for LOBEF stock?
What are the advantages of Conjugated Psilocin™ for LOBEF investors?
What is the primary target condition for Conjugated Psilocin™ development by LOBEF?
How long is the new patent for Conjugated Psilocin™ valid for LOBEF?
